Sanofi US News

- All six trials met primary efficacy endpoint -

IcyHot SmartRelief System Provides Physical Therapist-Trusted TENS Technology for Persistent, Chronic Back Pain Relief That Starts at the Touch of a Button

- Dupilumab Demonstrated Improvement in Lung Function, Reductions of Severe Exacerbations -

- Includes New Data Showing Fluzone High-Dose Vaccine More Efficacious Than Standard-Dose Fluzone Vaccine -

The two companies will develop a product jointly through phase II

More Than $83,000 Raised Benefiting Boys & Girls Clubs of NEPA, Employment Opportunity and Training Center, and Marley’s Mission

- Up to $200 Million Collaboration to Support Pioneering Science and New Treatments -

Approval aligns with Centers for Disease Control and Prevention's recommendations for meningococcal vaccination

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial -

- Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older -

- Study Demonstrates Fluzone High-Dose Vaccine 24.2 Percent More Effective Than Standard-Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older -

Generics Division of Sanofi, Winthrop US, to Market the Drug

- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor -

- Largest U.S. influenza vaccine supplier, providing broad product portfolio, will distribute at least 65 million doses to help protect people across multiple age groups against the virus this season -

- Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine –

- Toujeo dossier already accepted by EMA -